Clinical Research Malaysia (CRM) – Dr. Mohamed Ali Abu Bakar, CEO
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
Address: Aras 1-7, Blok C4 & C5, Kompleks C, Pusat Pentadbiran Kerajaan Persekutuan, 62662 Putrajaya, Wilayah Persekutuan,Malaysia
Tel: 8885 8000
The Ministry of Technology, Research and Innovation (MOSTI) is the Malaysian ministry in charge of research, telecommunication and information technology. The current minister is Datuk Dr. Maximus Ongkili.
MOSTI was first established in 1973 as the Ministry of Technology, Research and Local Government. Additional responsibility as the lead agency pertaining to environmental matters, the ministry then assumed its name Ministry of Science, Technology and Environment (MOSTE) in 1976. The formation of MOSTI came after the restructuring of MOSTE following the Cabinet decision on March 27, 2004.
In February 2007 were introduced a cluster approach (Biotechnology, ICT, Industry, Sea to Space and S&T Services). The National Innovation Model 2007 was introduced as well.
The objectives of the ministry are to move the economy up the value chain and raise the country’s capacity for knowledge, creativity and innovation and nurture first class mentality, which implies:
Increase productivity and competitiveness in agriculture, manufacturing and services sectors
Generate new sources of wealth in technology and knowledge-intensive sectors
Knowledge and innovation will be key determinants of Malaysia’s success as a KBE
Enhance innovation system that encourages top quality R&D and its commercialisation
MOSTI controls and supervises a number of institutions that are responsible in providing technical services to the government and the public. Besides divisions and agencies of the federal government, MOSTI also supervises companies set up by the government or through incorporation of a government body:
MIMOS Bhd (MIMOS)
Multimedia Development Corporation (MDeC)
SIRIM Bhd (SIRIM)
Technology Park Malaysia Corporation Sdn Bhd (TPM)
Malaysia Biotechnology Corporation (MBC)
Astronautic Technology Sdn Bhd (ATSB)
National ICT Security and Emergency Response Centre (NISER)
Malaysia Network Information Centre (MYNIC)
Malaysian Technology Development Corporation (MTDC)
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
The National Heart Institute’s CEO portrays IJN as a national referral center for cardiovascular disease and declares: “IJN is equipped with the best in class technologies and is poised to…
“We believe the future lies with Universal health coverage and the formulation of one and only healthcare, with the merger of public and private sector under one reimbursement system” says…
PEMANDU’s Director for the Healthcare National Key Economic Area gives a thorough understanding of the various entry point projects that were implemented since 2010 to help Malaysia become a high…
Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger…
PhAMA was started in 1972 and now has most of the MNC players among its members which include 43 companies. How has the association evolved since its origin and what…
The pharmaceutical industry has been targeted as one of the key growth sectors for the Malaysian economy under the 10th Malaysia Plan, how successful in your opinion have the government…
Without a doubt, Malaysia shares all the major attributes of an emerging market, from the potential to expand market penetration to the increasing purchasing power of the population. So…
2011 marks the 10th anniversary of the company. Over that time you’ve enjoyed notable success including being the first Asian CRO to attain OECD GLP accreditation. Talk us through your…
Since its origin, Emerging Pharma has been helping foreign pharma companies to enter Malaysia. However, the Malaysian market is relatively small. Why should international pharma companies look to this country…
How would you describe the operating environment for foreign companies to use the services of Malaysian companies and how can you reassure these multinationals that sufficient intellectual property protection is…
Malaysia has good ethnic diversity, cost-effective infrastructure, and highly qualified principal investigators (PIs) and these elements have been in place for a long time. Why is now is the right…
See our Cookie Privacy Policy Here